Northrop's $110 Billion Backlog, a 30% Drawdown, and a Foundry That's Suddenly For Sale

A good quarter into a bad tape

On the numbers, Northrop Grumman delivered almost everything an investor could ask for. Book-to-bill of 1.5x on over $16 billion of bookings pushed backlog to a record $110 billion, up 20% year over year. Sales rose 7% to $11.1 billion, segment operating margin cleared 12%, EPS of $7.89 rose 3%, and adjusted free cash flow of $1.8 billion was up more than 40%. Management raised 2026 segment operating income, margin rate and EPS, and — for the first time — set out 2027: 5% to 7% sales growth, 10 to 20 basis points of margin expansion, roughly $2.1 billion of capex and $3.3–3.7 billion of adjusted free cash flow.

The tape disagrees. NOC peaked at $768.02 on 2 March 2026 and has since given back 30.5%, and the last ninety days are a flat, listless drift, down 1.5% with a further 9.4% drawdown from the August high. That gap between a record backlog and a broken chart is the story of this print: the market is not paying for backlog, it is paying for program wins, and Northrop has been losing the marquee ones.

The price of that skepticism shows up in the valuation. At the last filed quarter the company traded at 20.6x trailing free cash flow, down 65% year over year, a de-rating that is hard to square with management's own claim that

for 2027, we expect about 35% of our backlog to burn down over the next 12 months, another 55% over the following 24 months… our backlog today is more robust and durable than what we would typically experience

That visibility claim is genuine and specific. It just isn't what the stock is trading on.

Fortitude: the foundry is the headline

Buried in the CEO's prepared remarks, past Sentinel and B-21, was the single most unusual sentence a defense prime can utter: Northrop is exploring strategic alternatives for its microelectronics and quantum businesses. The catalyst is FORTITUDE, a chip "the size of a grain of rice" delivering up to 3x the power and 20x the signal quality of comparable solutions, plus a two-decade-old quantum program built on patented reciprocal quantum logic. Warden's framing was explicit about the commercial angle:

we are actively evaluating strategic alternatives and believe we are uniquely positioned to lead in this field. We will share more details on our approach to scale this capability in the coming months.

Pressed on whether this means a sale or a spin, she gave the widest possible answer — sole investment, broadening the shareholder base, or separation — and to the question of a direct investment from the Office of Strategic Capital, she replied that “Everything is on the table.” — Kathy J. Warden, Chair, CEO and President · 2026-10-20 This is a genuine pivot, and the keyword set captures it: Microelectronics is a top gainer this quarter, alongside Quantum, FORTITUDE and the fresh strategic alternatives. The contrast with three months ago is sharp. In July, microelectronics was merely a soft spot — “growth in that business has been lower this year, particularly in our restricted microelectronics area, but we expect demand to increase over time.” — Kathy J. Warden, Chair, CEO and President · 2026-07-21 Now it is an asset being marked by someone other than Northrop. Note that CFO John Greene confirmed no investment dollars for quantum are in guidance yet, so this is optionality outside the numbers, not inside them.

The drone story the call didn't tell

Warden spent real airtime on Talon Blue, which flew a fully autonomous mission after being designed and built in 24 months, and on the TalonIQ test bed that has hosted roughly a half-dozen partner integrations. She leaned hard on ">over 5 thousand flight hours of experience with unmanned" and called the product line "a competitive entry in a market with clear growing demand signals." Demand signals is a phrase this company has recycled for over a year — it appeared in the 2023 and 2024 cycles too — and it is doing a lot of work here.

What went unsaid is that the Air Force's Collaborative Combat Aircraft increment-one awards went to two privately held entrants, not to Northrop. The keyword record is telling: collaborative combat aircraft ranked fourth for this company in Q1 2026; in the current quarter's top-30 it has vanished entirely, subsumed into Talon Blue and test-bed language. Asked directly about the slower increment one, Warden pivoted: “We are not waiting for but we are engaging with all of our customers… we are demonstrating capability so that customers can see the art of the possible.” — Kathy J. Warden, Chair, CEO and President · 2026-10-20 That is a graceful answer, and it is also a company that no longer has the contract. The adjacent win is cheaper: Counter UAS and RaidHunter, a gun-based short-range air defense line management says is drawing interest from key allies.

Margins, capex, and the fixed-price derisking

The margin picture is better than the headline. Last year's third quarter enjoyed a $68 million favorable adjustment at Mission Systems; this year's 12.1% segment rate was clean, and EAC adjustment risk — the GEM 63XL and Stand-in Attack Weapon charges that dominated the 2025 calls — has faded from the narrative. Management raised Mission Systems to the mid-15% range, then immediately tempered it: “MS, it is been a banner year in terms of execution there… where we are today, is likely on the upper end, and I would expect that to fall in a bit.” — John Thomas Greene, Chief Financial Officer · 2026-10-20 Meanwhile both Aeronautics and Defense Systems face basis-point pressure as B-21 and Sentinel take a larger share of sales — development revenue, lower margin, higher risk.

The offset is structural. Warden argued that as cost-plus development work converts to fixed price over the rest of the decade, "that derisks the portfolio" and reduces the earnings-adjustment choppiness that has plagued the stock. The cash cost of getting there is visible: capital expenditure of $302 million in the last filed quarter, up 31% year over year, with 2027 guided to about 4.5% of sales. Management is explicitly holding the free cash flow range while absorbing that — a credibility test that lands in 2027 and 2028.

Where does that leave the thesis? A record backlog, an accelerating growth algorithm and a genuinely novel strategic catalyst, against a chart that has already voted twice against this management team on program awards. The microelectronics review is the wildcard: a successful separation or outside capital injection would mark a business the market currently values at nothing, and would give investors a reason to look past the drone loss. Until then, Northrop is a company whose numbers are getting better while its story gets harder to tell.